The U.S. Food and Drug Administration today approved Esbriet (pirfenidone)
ピルフェニドン 吡非尼酮
for the treatment of idiopathic pulmonary fibrosis (IPF).
read at
see synthesis
Filed under: FDA 2014 Tagged: ピルフェニドン, Esbriet, FDA 2014, idiopathic pulmonary fibrosis, ipf, pirfenidone, 吡非尼酮
